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Impact of Mammography on
Breast Cancer Incidence in
Vaud, Switzerland
There are several indications that
breast cancer incidence is affected by
mammographic screening. On a
worldwide scale, for instance, breast
cancer incidence rates are consistently
highest in North America, where mam-
mographic screening is more widely
used [with about 30% of women report-
ing receiving a screening mammogram
in the previous year (7)]; however, mor-
tality is highest in Britain and other
western European countries (2). Over
the last decade, moreover, breast cancer
incidence has been rising in the United
States and various other developed
countries, although mortality has
remained constant (2). This geographi-
cal distribution and pattern of trends can
be explained, at least in part, by the dif-
ferent use of mammographic screening
in various populations. For example, a
survey based on data from the Utah
Cancer Registry (3) found that ap-
proximately 30% of all breast cancer
cases were discovered by mam-
mograms; among women 50-79 years
old, the percentage thus detected is par-
ticularly high. To provide information
representative of a European population,
we Conducted a survey on the process of
breast cancer diagnosis of incident cases
based on the data from the Vaud Cancer
Registry in Switzerland.
The series was composed of 376 inci-
dent cases of breast cancer registered in
1989 and abstracted from the Vaud Can-
cer Registry file, which includes data
concerning cases of malignant neo-
plasms in the Canton of Vaud, whose
population was about 570 000 in 1989
(4). We sent a questionnaire to
physicians to obtain information on
clinical stage (TNM) and method of
diagnosis (i.e., detected by the patient,
medical examination, mammography, or
other procedure). A total of 344 (91%)
responses were obtained. No informa-
tion on diagnostic method was available
from 32 (9%) of the cases. Information
on clinical stage of diagnosis was avail-
able for 367 (97%) cases. The remain-
ing nine cases were assumed to be
advanced tumors.
Of the 376 registered cases, only 32
(9%) were discovered through mam-
mography, 81 (22%) by medical ex-
amination, 217 (58%) were detected by
the patients themselves, and 46 (12%)
patients could not provide reliable infor-
mation on process of detection.
The distribution of cases by method
of diagnosis and decade of age is given
in Fig. 1. The highest proportion of
cases detected by mammography (20%)
was in women between the ages of 50
and 59, followed by women ages 60 to
69 (12%) years. No case was found at
mammographic screening in women
under the age of 35 years and only one
case was found in a patient over the age
of 70.
These 376 incident cases of breast
cancer are further considered in Table 1
according to stage at diagnosis and
overall age group. Cases of breast can-
cer detected by mammography were
more frequently in a localized stage
(56%) and less frequently in an ad-
vanced stage (6%) than those dis-
covered by the patients themselves or by
physical examination (about 30% local-
ized, between 16% and 24% advanced),
with no major difference between the
two groups. The most advanced stage at
presentation was found among women
with an undefined process of discovery
and particularly among those aged 55 or
more years of age.
In Vaud, breast cancer incidence rose
by 9% (from 65.4 to 71.4 per 100 000
[world standard]) between 1978 and
1988 (6,7), while on a national level in
Switzerland, mortality rates have in-
creased by approximately 10% during
the same time period (8,9).
All of these estimates are subject to
random variation and other sources of
error or bias, which introduce substan-
tial uncertainties in any interpretation.
Still, the data presented do not suggest
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Fig. 1. Distribution of 376 incidence cases of breast cancer by method of diagnosis and age group in
Vaud, Switzerland, 1989.
Table 1. Percent distribution of 376 incident cases of breast cancer according to method of discovery,
age, and stage at diagnosis, Vaud, Switzerland, 1989
Method of diagnosis
Mammography
Medical examination
Patient's detection
Other or unspecifiedt
Age<55
stage
1
62.5
40.0
39.5
30.8
2
31.3
56.7
52.6
38.5
y.
3*
6.3
3.3
7.9
30.8
1
50.0
29.4
24.1
12.1
Age £55 y,
stage
2
43.8
47.1
44.0
39.4
3*
6.3
23.5
31.9
48.5
1
56.3
33.3
29.5
17.4
Total,
SWRC
2
37.5
50.6
47.0
39.1
3*
6.3
16.0
23.5
43.5
No. of
cases
32
81
217
46
•Includes TNM stages III (n = 58), IV (n = 19), or unknown (n = 9).
t Includes 32 cases (8.5%) for whom there was no response to the survey.
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that the low rate of mammographic
screening used in this European popula-
tion has, to date, introduced substantial
modifications in breast cancer incidence
trends.
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Response
The data on methods of breast cancer
detection in Switzerland (J) provide an
interesting contrast to the data from the
Utah study (2). The studies were fairly
similar, but were conducted in areas
with quite different levels of mam-
mographic screening and different in-
cidence and mortality rates as well as
changes in these rates. Taken together,
the results of the studies support the
hypotheses that mammographic screen-
ing is effective in early detection, but
that increased levels of screening may
result, at least temporarily, in increased
breast cancer incidence rates, particular-
ly in women between the ages of 45 and
75 years. Other studies published in this
Journal recently have also supported
these hypotheses (3,4). Another ex-
planation for some of the recent in-
creases in breast cancer rates involves
exogenous estrogens. It would be of in-
terest to compare the estrogen ex-
perience in areas such as in the two
above studies.
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Aspirin Use and Incidence of
Large-Bowel Cancer in a
California Retirement
Community
Rosenberg and colleagues recently
suggested that sustained use of non-
steroidal anti-inflammatory drugs
(NSAIDs) reduces the incidence of
large-bowel cancer (/). In a hospital-
based case-control study, they found
that the relative risk for large-bowel
cancer for regular NSAID use, which
was begun within the year before the in-
terview, was 0.4. This contrasts with our
previously reported finding of some in-
creased risk of colon cancer with daily
aspirin use (2). In this prospective
cohort study of the 13 987 residents of
Leisure World, Laguna Hills, Calif., the
sex- and age-adjusted relative risk of
colon cancer was 1.5 (95% confidence
interval = 1.1 to 2.2) for daily aspirin
users relative to non-users.
For this study, we mailed a detailed
health questionnaire to all residents of
this southern California retirement com-
munity in June 1981. This questionnaire
included information on previous medi-
cal diagnoses including cancer and use
of nonprescription analgesics. The
cohort had follow-up that included all
hospital admissions to three hospitals
serving the area and for additional can-
cers reported to the tumor registries of
five hospitals and of the Cancer Surveil-
lance Programs of Orange County and
of Los Angeles County. Death certifi-
cates were obtained for all decedents
identified by search of the death records
of the local health department, the
obituary column of the local newspaper,
information provided by relatives and
friends, and by search of the National
Death Index.
We extended our follow-up for two
additional years. As of January 1, 1990,
we had identified 231 incident cases of
colon cancer among those who initially
reported that they had not had colon
cancer. We again found no evidence of
a protective effect of aspirin on colon
cancer risk (Table 1). With daily aspirin
use, the relative risk of colon cancer was
1.46 in males and 1.01 in females. Sub-
dividing cases of colon cancer further
into right-sided (cecum to hepatic flex-
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